Submission Deadline
31 Jan 2023 (Vol 46 , Iss 02 )

Upcoming Publication
31 Jan 2023 (Vol 46 , Iss 01 )


Teikyo Medical Journal

Journal ID : TMJ-28-12-2022-11476
Total View : 471

Title : Assessment of progastrin releasing peptide as a biomarker in early detection of non-muscle invasive bladder cancer patients; A prospective multicentric study

Abstract :

Bladder tumors are frequently diagnosed as urologic malignant diseases and mostly identified in their incipient form as non-muscle invasive. The diagnosis of bladder carcinoma at this moment is established using cytology and cystoscopy and is a great challenge for clinicians due to the lack of sensitivity and specificity. Biomarkers could improve and enhance the diagnosis and screening techniques. To evaluate the usefulness of serological and urological progastrin releasing peptide levels as a biomarker for the diagnosis of non-muscle invasive bladder cancer. In this study, Patients were first diagnosed pathologically at our teaching hospital and oncology center. Eighty subjects were recruited and divided into three groups: Ta Non-muscle invasive bladder cancer patients (n= 26), T1 Non-muscle invasive bladder cancer patients (n= 24) and thirty healthy control subjects. Serum and urine samples were collected from patients and had their serum progastrin releasing peptide levels measured using enzyme-linked immunosorbent assay. Statistical analyses were used to reveal the associations therein. Progastrin releasing peptide was significantly elevated in serum and urine of non-muscle invasive bladder cancer (Ta and T1) patients (P < 0.0001); compared to control group, but its levels were higher in Ta Non-muscle invasive bladder cancer than T1 Non-muscle invasive bladder cancer. Progastrin releasing peptide assay is a simple and inexpensive test, and might serve as a potential serological and urological biomarker for non-muscle-invasive bladder cancer patients, especially, in the early stages Ta Non-muscle invasive bladder cancer.

Full article
Journal ID : TMJ-28-12-2022-11474
Total View : 438


Abstract :

In recent years, the blood groups of patients have begun to attract the attention of researchers, which is associated with natural selection and genetic load in the human population. Non-random distributions of the alleles of the erythrocyte antigen ABO on the planet have been established, associated with different survival rates of individuals differing in blood type in conditions of frequent epidemics of particularly dangerous infections. The regions of relatively low frequencies of the allele of the first blood group O (I) and relatively high frequencies of the allele of the third group B (III) in Central Asia coincide with the foci of plague, the causative agent of which has an H-antigen, populations with the first blood group, a group especially susceptible to plague. The proof is the fact that relatively high concentrations of the allele of the first group were found in the populations of aborigines of Australia and Polynesia, American Indians, who were practically not infected with the plague. In addition, for populations from the same geographical region, but isolated reproductively, the reason for the sharp difference in the concentration of ABO alleles may be gene drift. For example, the frequency of blood group A (I) reaches 80% among the Indians of the Blackfoot tribe and 20% among the Indians from Utah [Yarygin V.N., 1999]. Our task was to study the susceptibility to pneumonia and parasitic diseases, mainly echinococcosis among healthy and sick children, depending on the blood type. What is the susceptibility to helminthiasis in people of different blood groups.

Full article

Journal Visit

Top Visit

Medium Visit

Less Visit

Not Visit